Makino Ryutaro, Higa Nayuta, Akahane Toshiaki, Yonezawa Hajime, Uchida Hiroyuki, Takajo Tomoko, Fujio Shingo, Kirishima Mari, Hamada Taiji, Yamahata Hitoshi, Kamimura Kiyohisa, Yoshiura Takashi, Yoshimoto Koji, Tanimoto Akihide, Hanaya Ryosuke
Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Department of Pathology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Neurooncol Adv. 2023 Sep 2;5(1):vdad110. doi: 10.1093/noajnl/vdad110. eCollection 2023 Jan-Dec.
Glioblastoma (GBM) is a malignant brain tumor, with radiological and genetic heterogeneity. We examined the association between radiological characteristics and driver gene alterations.
We analyzed the driver genes of 124 patients with wild-type GBM with contrast enhancement using magnetic resonance imaging. We used a next-generation sequencing panel to identify mutations in driver genes and matched them with radiological information. Contrast-enhancing lesion localization of GBMs was classified into 4 groups based on their relationship with the subventricular zone (SVZ) and cortex (Ctx).
The cohort included 69 men (55.6%) and 55 women (44.4%) with a mean age of 66.4 ± 13.3 years. and alterations were detected in 28.2% and 22.6% of the patients, respectively. Contrast-enhancing lesion touching both the SVZ and Ctx was excluded because it was difficult to determine whether it originated from the SVZ or Ctx. Contrast-enhancing lesions touching the SVZ but not the Ctx had significantly worse overall survival than non-SVZ lesions (441 days vs. 897 days, = .002). GBM touching only the Ctx had a better prognosis (901 days vs. 473 days, < .001) than non-Ctx lesions and was associated with alteration (39.4% vs. 13.2%, = .015). Multiple contrast lesions were predominant in alteration and -wild type ( = .036 and = .031, respectively).
alteration was associated with cortical lesions. And alteration correlated with multiple lesions. Our results suggest that clarifying the association between driver genes and tumor localization may be useful in clinical practice, including prognosis prediction.
胶质母细胞瘤(GBM)是一种恶性脑肿瘤,具有放射学和基因异质性。我们研究了放射学特征与驱动基因改变之间的关联。
我们分析了124例使用磁共振成像显示有对比增强的野生型GBM患者的驱动基因。我们使用下一代测序面板来鉴定驱动基因中的突变,并将其与放射学信息进行匹配。根据GBM对比增强病变与脑室下区(SVZ)和皮质(Ctx)的关系,将其分为4组。
该队列包括69名男性(55.6%)和55名女性(44.4%),平均年龄为66.4±13.3岁。分别在28.2%和22.6%的患者中检测到 和 改变。由于难以确定对比增强病变是起源于SVZ还是Ctx,因此排除了同时接触SVZ和Ctx的病变。接触SVZ但不接触Ctx的对比增强病变的总生存期明显低于非SVZ病变(441天对897天, =0.002)。仅接触Ctx的GBM比非Ctx病变预后更好(901天对473天, <0.001),并且与 改变相关(39.4%对13.2%, =0.015)。多个对比病变在 改变和 -野生型中占主导(分别为 =0.036和 =0.031)。
改变与皮质病变相关。并且 改变与多个病变相关。我们的结果表明,阐明驱动基因与肿瘤定位之间的关联可能在临床实践中有用,包括预后预测。